Telomir Pharmaceuticals (TELO) Other Non-Current Liabilities (2022 - 2024)
Telomir Pharmaceuticals (TELO) posted Other Non-Current Liabilities of $500000.0 for Q4 2024, up 435.15% sequentially from $93432.0 in Q3 2024, and down 5.19% YoY from $527377.0 in Q1 2024.
Telomir Pharmaceuticals (TELO) Other Non-Current Liabilities (2022 - 2024) Analysis & Trends
Telomir Pharmaceuticals has reported Other Non-Current Liabilities for 3 years, with the latest figure at $500000.0 in Q4 2024.
- Quarterly Other Non-Current Liabilities fell 5.19% year-over-year to $500000.0 in Q4 2024, while the trailing twelve-month figure through Dec 2024 was $500000.0 (down 5.19% YoY) and the FY2024 annual result came in at $500000.0, down 5.19% from the prior year.
- Other Non-Current Liabilities climbed to $500000.0 in Q4 2024 per TELO's latest filing, from $93432.0 in the prior quarter.
- Over five years, Other Non-Current Liabilities peaked at $581787.0 in Q4 2022 and troughed at $7902.0 in Q1 2024.
- A 3-year average of $308473.2 and a median of $320170.5 in 2024 frame the typical range for Other Non-Current Liabilities.
- The sharpest annual moves came in 2023 and 2024: Other Non-Current Liabilities dropped 9.35% in 2023, then declined 5.19% in 2024.
- Over 3 years, Other Non-Current Liabilities stood at $581787.0 in 2022, then retreated by 9.35% to $527377.0 in 2023, then slipped by 5.19% to $500000.0 in 2024.
- According to Business Quant data, Other Non-Current Liabilities over the past three periods registered $500000.0, $93432.0, and $140341.0 for Q4 2024, Q3 2024, and Q2 2024 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.40 Bn | 131.55 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 86.53 Bn | 78.54 Bn | 3.93 Bn |
| 3 | Argenx Se | 65.20 Bn | 60.02 Bn | 1.37 Bn |
| 4 | Moderna | 60.40 Bn | 55.26 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 42.17 Bn | 37.07 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.36 Bn | 28.05 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.74 Bn | 10.34 Bn | 668.28 Mn |
| 8 | Insmed | 27.45 Bn | 26.29 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.17 Bn | 26.33 Bn | - |
| 10 | Telomir Pharmaceuticals | 69.96 Mn | 69.96 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 500,000.00 |
| Sep 30, 2024 | 93,432.00 |
| Jun 30, 2024 | 140,341.00 |
| Mar 31, 2024 | 7,902.00 |
| Dec 31, 2023 | 527,377.00 |
| Dec 31, 2022 | 581,787.00 |